These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
208 related articles for article (PubMed ID: 15981212)
1. Hyperforin, a bio-active compound of St. John's Wort, is a new inhibitor of angiogenesis targeting several key steps of the process. Martínez-Poveda B; Quesada AR; Medina MA Int J Cancer; 2005 Dec; 117(5):775-80. PubMed ID: 15981212 [TBL] [Abstract][Full Text] [Related]
2. Functional induction and de-induction of P-glycoprotein by St. John's wort and its ingredients in a human colon adenocarcinoma cell line. Tian R; Koyabu N; Morimoto S; Shoyama Y; Ohtani H; Sawada Y Drug Metab Dispos; 2005 Apr; 33(4):547-54. PubMed ID: 15640377 [TBL] [Abstract][Full Text] [Related]
3. Tetrahydrohyperforin and octahydrohyperforin are two new potent inhibitors of angiogenesis. Martínez-Poveda B; Verotta L; Bombardelli E; Quesada AR; Medina MA PLoS One; 2010 Mar; 5(3):e9558. PubMed ID: 20224821 [TBL] [Abstract][Full Text] [Related]
4. Hyperforin acts as an angiogenesis inhibitor. Schempp CM; Kiss J; Kirkin V; Averbeck M; Simon-Haarhaus B; Kremer B; Termeer CC; Sleeman J; Simon JC Planta Med; 2005 Nov; 71(11):999-1004. PubMed ID: 16320199 [TBL] [Abstract][Full Text] [Related]
5. Hyperforin: more than an antidepressant bioactive compound? Medina MA; Martínez-Poveda B; Amores-Sánchez MI; Quesada AR Life Sci; 2006 Jun; 79(2):105-11. PubMed ID: 16438991 [TBL] [Abstract][Full Text] [Related]
6. Hyperforin and aristoforin inhibit lymphatic endothelial cell proliferation in vitro and suppress tumor-induced lymphangiogenesis in vivo. Rothley M; Schmid A; Thiele W; Schacht V; Plaumann D; Gartner M; Yektaoglu A; Bruyère F; Noël A; Giannis A; Sleeman JP Int J Cancer; 2009 Jul; 125(1):34-42. PubMed ID: 19326439 [TBL] [Abstract][Full Text] [Related]
7. Hyperforin, the active component of St. John's wort, induces IL-8 expression in human intestinal epithelial cells via a MAPK-dependent, NF-kappaB-independent pathway. Zhou C; Tabb MM; Sadatrafiei A; Grün F; Sun A; Blumberg B J Clin Immunol; 2004 Nov; 24(6):623-36. PubMed ID: 15622447 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of tumour cell growth by hyperforin, a novel anticancer drug from St. John's wort that acts by induction of apoptosis. Schempp CM; Kirkin V; Simon-Haarhaus B; Kersten A; Kiss J; Termeer CC; Gilb B; Kaufmann T; Borner C; Sleeman JP; Simon JC Oncogene; 2002 Feb; 21(8):1242-50. PubMed ID: 11850844 [TBL] [Abstract][Full Text] [Related]
9. Role of hyperforin in the pharmacological activities of St. John's Wort. Zanoli P CNS Drug Rev; 2004; 10(3):203-18. PubMed ID: 15492771 [TBL] [Abstract][Full Text] [Related]
10. Protective effects of St. John's wort extract and its component hyperforin against cytokine-induced cytotoxicity in a pancreatic beta-cell line. Menegazzi M; Novelli M; Beffy P; D'Aleo V; Tedeschi E; Lupi R; Zoratti E; Marchetti P; Suzuki H; Masiello P Int J Biochem Cell Biol; 2008; 40(8):1509-21. PubMed ID: 18226577 [TBL] [Abstract][Full Text] [Related]
11. Hyperforin--a key constituent of St. John's wort specifically activates TRPC6 channels. Leuner K; Kazanski V; Müller M; Essin K; Henke B; Gollasch M; Harteneck C; Müller WE FASEB J; 2007 Dec; 21(14):4101-11. PubMed ID: 17666455 [TBL] [Abstract][Full Text] [Related]
12. NMDA receptor-antagonistic properties of hyperforin, a constituent of St. John's Wort. Kumar V; Mdzinarishvili A; Kiewert C; Abbruscato T; Bickel U; van der Schyf CJ; Klein J J Pharmacol Sci; 2006 Sep; 102(1):47-54. PubMed ID: 16936454 [TBL] [Abstract][Full Text] [Related]
13. Effect of the St. John's wort constituent hyperforin on docetaxel metabolism by human hepatocyte cultures. Komoroski BJ; Parise RA; Egorin MJ; Strom SC; Venkataramanan R Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6972-9. PubMed ID: 16203790 [TBL] [Abstract][Full Text] [Related]
14. Mechanisms of Hyperforin as an anti-angiogenic angioprevention agent. Lorusso G; Vannini N; Sogno I; Generoso L; Garbisa S; Noonan DM; Albini A Eur J Cancer; 2009 May; 45(8):1474-84. PubMed ID: 19223175 [TBL] [Abstract][Full Text] [Related]
15. Hyperforin a constituent of St John's wort (Hypericum perforatum L.) extract induces apoptosis by triggering activation of caspases and with hypericin synergistically exerts cytotoxicity towards human malignant cell lines. Hostanska K; Reichling J; Bommer S; Weber M; Saller R Eur J Pharm Biopharm; 2003 Jul; 56(1):121-32. PubMed ID: 12837490 [TBL] [Abstract][Full Text] [Related]
16. Induction and inhibition of cytochromes P450 by the St. John's wort constituent hyperforin in human hepatocyte cultures. Komoroski BJ; Zhang S; Cai H; Hutzler JM; Frye R; Tracy TS; Strom SC; Lehmann T; Ang CY; Cui YY; Venkataramanan R Drug Metab Dispos; 2004 May; 32(5):512-8. PubMed ID: 15100173 [TBL] [Abstract][Full Text] [Related]
17. [Hypericin and hyperforin: bioactive components of St. John's Wort (Hypericum perforatum). Their isolation, analysis and study of physiological effect]. Vacek J; Klejdus B; Kubán V Ceska Slov Farm; 2007 Apr; 56(2):62-6. PubMed ID: 17619301 [TBL] [Abstract][Full Text] [Related]
18. Quantitative characterization of direct P-glycoprotein inhibition by St John's wort constituents hypericin and hyperforin. Wang EJ; Barecki-Roach M; Johnson WW J Pharm Pharmacol; 2004 Jan; 56(1):123-8. PubMed ID: 14980009 [TBL] [Abstract][Full Text] [Related]
19. Topical application of St John's wort (Hypericum perforatum L.) and of its metabolite hyperforin inhibits the allostimulatory capacity of epidermal cells. Schempp CM; Winghofer B; Lüdtke R; Simon-Haarhaus B; Schöpf E; Simon JC Br J Dermatol; 2000 May; 142(5):979-84. PubMed ID: 10809859 [TBL] [Abstract][Full Text] [Related]
20. Downregulation of β1 -adrenergic receptors in rat C6 glioblastoma cells by hyperforin and hyperoside from St John's wort. Jakobs D; Hage-Hülsmann A; Prenner L; Kolb C; Weiser D; Häberlein H J Pharm Pharmacol; 2013 Jun; 65(6):907-15. PubMed ID: 23647684 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]